title: Biologics in cervical cancer therapy.
abstract: Though cervical cancer incidence and prevalence have decreased in the United States, the disease remains a very important cause of morbidity and mortality worldwide. Current therapy for early-stage disease is surgical with adjuvant therapy being administered according to histopathologic findings. Pelvic radiation with concomitant platinum-based chemotherapy is used to treat locally advanced disease, whereas metastatic and recurrent lesions continue to be difficult to effectively treat and cure. Clinical trials in this latter scenario have suggested that clinical benefit may be associated with biologic therapies. This article focuses on the use of targeted therapies in cervical cancer, specifically evaluating antiangiogenesis and endothelial growth factor receptor-related treatments.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center at the University of California Irvine Medical Center, USA.
authors.forename: Lyndsay J
authors.initials: LJ
authors.lastname: Willmott
authors.forename: Daniele A
authors.initials: DA
authors.lastname: Sumner
authors.forename: Bradley J
authors.initials: BJ
authors.lastname: Monk
mesh_terms: D001688:Biological Products / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000378:metabolism; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D002583:Uterine Cervical Neoplasms / Q000628:therapy*; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors
chemical_list: D001688:Biological Products; D042442:Vascular Endothelial Growth Factors; D040262:Receptors, Vascular Endothelial Growth Factor